SAT-175 Trial in Progress Interim Report: A Phase II Clinical Trial Using Single Agent Cabozantinib in Advanced Adrenocortical Carcinoma

BACKGROUND: Adrenocortical carcinoma (ACC) in an aggressive malignancy with suboptimal response to frontline chemotherapy and without established second line treatment. cMET activation is associated with ACC resistance to chemotherapy. Cabozantinib is a multi-kinase inhibitor that targets the VEGFR,...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Endocr Soc
Main Authors: Bedrose, Sara Shokry Daniel, Altameemi, Lina, Daher, Marilyne, De Rosa, Gina Tamsen, Varghese, Jeena Mary, Jimenez, Camilo, Campbell, Matthew, Habra, Mouhammed Amir
Format: Artigo
Sprog:Inglês
Udgivet: Oxford University Press 2020
Fag:
Adrenal
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7209711/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvaa046.508
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker